The TAT-RasGAP(317-326) anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner

Tumor cell resistance to apoptosis, which is triggered by many anti-tumor therapies, remains a major clinical problem. Therefore, development of more efficient therapies is a priority to improve cancer prognosis. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase...

Descripción completa

Detalles Bibliográficos
Autores principales: Heulot, Mathieu, Chevalier, Nadja, Puyal, Julien, Margue, Christiane, Michel, Sébastien, Kreis, Stephanie, Kulms, Dagmar, Barras, David, Nahimana, Aimable, Widmann, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325447/
https://www.ncbi.nlm.nih.gov/pubmed/27602963
http://dx.doi.org/10.18632/oncotarget.11841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325447/
https://www.ncbi.nlm.nih.gov/pubmed/27602963
http://dx.doi.org/10.18632/oncotarget.11841

Ejemplares similares